Healthcare
Vaccinex, Inc.(VCNX)
Live Price
Offline$1.11
+11.00% today
1Y Change
+30.77%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- โ
- Revenue Growth
- +5.4%
- EPS Growth
- +79.7%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vaccinex, Inc. (VCNX) is a Healthcare stock with listed on OTC. The stock last traded around $1.11 and up 30.8% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +5.4%, EPS growth of +79.7%, a dividend yield of 0.0%. What stands out right now is revenue +5.4%, EPS +79.7%, free cash flow +6.3% with operating margin -3117.3% and ROIC 760.7%. Valuation sits in the middle of the pack at price/sales 4.5. Stock Foundry combines VCNX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.4% vs +7.6% peer median
Operating Margin
Below sector median
-3117.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +5.4% and EPS at +79.7%, with operating margin around -3117.3%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 10, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 29, 2026 | โ | +0.0% | +0.0% | โ |
2026 May 18, 2026 | โ | +0.0% | -4.5% | -9.1% |
2026 Feb 25, 2026 | โ | +0.0% | +21.4% | +1.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VCNX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VCNX Max Drawdown
-67.62%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VCNX and SPY.
Company Overview
Vaccinex, Inc.
Other OTC
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
- Leadership
- Maurice Zauderer
- IPO Date
- Aug 9, 2018
- Employees
- 23
- Street Address
- 1895 Mount Hope Avenue
- Mailing
- Rochester, NY, 14620
- Region
- Rochester, NY, US
- Reporting Currency
- USD
- Investor Line
- 585 271 2700
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.5
- Price/Book
- โ
Growth
- Revenue
- +5.4%
- EPS
- +79.7%
- Free Cash Flow
- +6.3%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -3117.3%
- Net Margin
- -3100.5%
- ROE
- 776.6%
- ROIC
- 760.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.